Happiness and depression in psoriasis: a cross-sectional study in Germany.
Depression
Dermatology
Happiness
Mental health
Psoriasis
Subjective well-being
Journal
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
accepted:
31
08
2021
pubmed:
18
9
2021
medline:
18
5
2022
entrez:
17
9
2021
Statut:
ppublish
Résumé
Prior research on the psychological consequences of skin diseases has focused on assessing mental comorbidities. The aim of this study was to investigate subjective well-being in a large sample of individuals affected by psoriasis, a chronic inflammatory skin disease, and to explore the associations with depression and disease-related parameters such as disease severity. A cross-sectional online survey was conducted from March to June 2019. The link to the questionnaire was shared on websites and Facebook pages of psoriasis patient organizations and campaigns. Participants filled in validated scales measuring subjective well-being-operationalized as positive affect (PA), negative affect (NA) and satisfaction with life (SWL); and depression. The data of 722 participants were analyzed. Exploratory factor analysis supported the differentiation of PA, NA, SWL, and depression as four different constructs. The respondents reported lower levels of PA than healthy individuals and judged themselves to be less happy and were less satisfied with their lives than the general population (except age group 65 + years). 40.3% of respondents were screened positive for depression. More severe psoriasis was associated with lower affective well-being and a higher risk for depression. The results of this study empirically supported the differentiation of subjective well-being and depression as different constructs in individuals with psoriasis, and underline the large mental burden of the disease which goes beyond a higher risk for depression. Measures of well-being should thus be incorporated in both research and clinical practice in patients with psoriasis in order to achieve a more comprehensive picture of the mental burden of this disease.
Identifiants
pubmed: 34532835
doi: 10.1007/s11136-021-02991-2
pii: 10.1007/s11136-021-02991-2
pmc: PMC9098583
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1761-1773Informations de copyright
© 2021. The Author(s).
Références
Br J Dermatol. 2002 Mar;146(3):458-65
pubmed: 11952546
J Am Acad Dermatol. 2021 Jun;84(6):1730-1732
pubmed: 32861712
J Pers Soc Psychol. 1988 Jun;54(6):1063-70
pubmed: 3397865
Psychol Bull. 1984 May;95(3):542-75
pubmed: 6399758
Lancet. 2015 Sep 5;386(9997):983-94
pubmed: 26025581
Psychol Bull. 1988 Mar;103(2):265-275
pubmed: 3363047
Int J Dermatol. 2007 Oct;46(10):1042-5
pubmed: 17910711
Acta Derm Venereol. 2012 Jan;92(1):67-72
pubmed: 21879243
Psychometrika. 1965 Jun;30:179-85
pubmed: 14306381
J Dermatolog Treat. 2019 Aug;30(5):435-440
pubmed: 30256690
Health Psychol. 2009 May;28(3):373-8
pubmed: 19450044
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1331-1339
pubmed: 31838769
Qual Life Res. 2021 Jan;30(1):181-191
pubmed: 32888104
J Eur Acad Dermatol Venereol. 2019 Jul;33(7):1316-1324
pubmed: 31736536
Eur J Dermatol. 2021 Dec 1;31(6):722-729
pubmed: 34726161
Acta Derm Venereol. 2016 Aug 23;96(217):47-50
pubmed: 27283435
Postepy Hig Med Dosw (Online). 2017 Dec 11;71(0):1115-1122
pubmed: 29225203
J Cutan Med Surg. 2021 May-Jun;25(3):257-270
pubmed: 33263264
JAMA Dermatol. 2019 Jun 1;155(6):745-747
pubmed: 31066861
PLoS One. 2017 Feb 8;12(2):e0171288
pubmed: 28178328
J Eur Acad Dermatol Venereol. 2017 Feb;31(2):205-212
pubmed: 27573025
J Pers. 2009 Dec;77(6):1747-76
pubmed: 19796062
J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1308-1315
pubmed: 28281329
J Pers Assess. 1985 Feb;49(1):71-5
pubmed: 16367493
J Eur Acad Dermatol Venereol. 2019 Jul;33(7):1421-1428
pubmed: 30891839
J Adult Dev. 2010 Jun;17(2):110-119
pubmed: 20502508
Behav Res Methods. 2006 Feb;38(1):88-91
pubmed: 16817517
Int J Behav Med. 2012 Sep;19(3):260-9
pubmed: 21706200
Eur J Dermatol. 2015 Jul-Aug;25(4):329-34
pubmed: 26065886
J Invest Dermatol. 2014 Jun;134(6):1542-1551
pubmed: 24284419
BMC Psychol. 2016 Feb 10;4:8
pubmed: 26865173
Pharmacoeconomics. 2021 Jun;39(6):627-630
pubmed: 33135149
J Invest Dermatol. 2015 Apr;135(4):984-991
pubmed: 25521458
Psychother Psychosom. 2005;74(5):315-22
pubmed: 16088270
Int J Dermatol. 2018 Oct;57(10):1165-1172
pubmed: 29729012
JAMA Dermatol. 2019 Dec 1;155(12):1380-1389
pubmed: 31617856
Behav Res Methods. 2021 Dec;53(6):2576-2590
pubmed: 33963496
J Affect Disord. 2004 Feb;78(2):131-40
pubmed: 14706723
Eur J Dermatol. 2014 Mar-Apr;24(2):242-7
pubmed: 24721720
Acta Derm Venereol. 2007;87(4):317-24
pubmed: 17598034
J Eur Acad Dermatol Venereol. 2016 Jul;30(7):1159-64
pubmed: 27027485
Acta Derm Venereol. 2016 Aug 23;96(217):69-73
pubmed: 27283722
J Am Acad Dermatol. 2018 Jan;78(1):70-80
pubmed: 29102053
Postepy Dermatol Alergol. 2013 Apr;30(2):85-90
pubmed: 24278053